Tags : Prostate Cancer

AstraZeneca and MSD Report Results of Lynparza in P-III PROfound

Shots::stososohhhhththShots: The P-III PROfound study involves assessing of Lynparza vs enzalutamide or abiraterone in patients with mCRPC, progressed on prior treatment with NHA treatments (abiraterone or enzalutamide) along with tumor mutation in BRCA1/2, ATM or one of 12 other genes involved in the HRR pathway The P-III PROfound study demonstrated improvement in OS and is […]Read More

Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx

Shots: Janssen and Resolution Bioscience develops Resolution’s HRD liquid biopsy test as a companion diagnostic for Janssen’s Niraparib, being investigated for the treatment of metastatic castration-resistant prostate cancer The Resolution HRD assay will allow Janssen to identify patients with prostate cancer who may benefit from Niraparib therapy. In 2016, Janssen got exclusive WW license from […]Read More